Cover Image
市場調查報告書

胃癌治療藥的R&D、市場趨勢、市場預測:2016-2026年

Gastric Cancer Drugs - R&D, Trends and Market Forecasts 2016-2026

出版商 Visiongain Ltd 商品編碼 365147
出版日期 內容資訊 英文 147 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
胃癌治療藥的R&D、市場趨勢、市場預測:2016-2026年 Gastric Cancer Drugs - R&D, Trends and Market Forecasts 2016-2026
出版日期: 2016年06月28日 內容資訊: 英文 147 Pages
簡介

本報告提供全球胃癌治療藥的市場調查,胃癌治療及胃癌治療藥概要,主要的胃癌治療藥概要,收益的變化與預測,研發產品線趨勢,各藥物種類的市場規模的變化與預測,推動市場成長的要素與阻礙要素分析,主要國家、新興國家的趨勢,專家的見解等彙整資料。

第1章 報告概要

第2章 簡介:胃癌治療

  • 胃癌:概要
  • 胃癌的治療
  • 胃癌治療市場定義

第3章 主要胃癌治療藥

  • Herceptin (Trastuzumab):Roche
    • 收益預測
  • Cyramza (ramucirumab):Eli Lilly
    • 收益預測
  • Taxotere (Docetaxel ):Sanofi
    • 收益預測
  • Xeloda (Capecitabine):Roche
    • 收益預測
  • Abraxane (Paclitaxel蛋白質結合粒子):Celgene/大鵬藥品工業/大塚製藥
    • 收益預測
  • TS-1 (S-1/Teysuno):大鵬藥品工業/大塚製藥
    • 收益預測
  • Apatinib (YN968D1):Jiangsu Hengrui Medicine/LSK BioPartners/Bukwang Pharmaceutical Company
    • 收益預測

第4章 胃癌治療藥:研發產品線分析、預測

  • 胃癌治療部門的R&D的重要性
  • Perjeta (pertuzumab):Roche
  • Opdivo (nivolumab/ONO-4538):Bristol-Myers Squibb
  • Keytruda (pembrolizumab/MK3475):Merck/MSD
  • TAS-118:大鵬藥品工業/大塚製藥
  • TAS-102:大鵬藥品工業/大塚製藥/Servier
  • NeuVax (nelipepimut-S):Galena Biopharma/Dr. Reddy's Laboratories
  • Ipatasertib (GDC-0068/RG7440):Genentech/Roche/Array BioPharma
  • Durvalumab (MEDI4736):AstraZeneca/MedImmune
  • Avelumab- (MSB0010718C):Merck KGaA/Pfizer
  • Claudiximab (IMAB362):Ganymed Pharmaceutical
  • Napabucasin (BBI608):Boston Biomedical
  • AZD4547:AstraZeneca
  • Dovitinib (TKI258):Novartis
  • 胃癌治療:未來展望

第5章 胃癌治療藥:全球市場的預測、SWOT分析

  • 全球市場的預測
  • 全球收益預測
  • 市場預測:化療部門
  • 市場預測:單株抗體部門
  • 市場預測:血管新生抑制劑部門
  • 市場促進因素、阻礙要素
  • SWOT分析

第6章 胃癌治療藥:主要國家市場預測

  • 全球胃癌治療藥市場:各地區
  • 各地區預測
  • 美國
  • 歐盟5國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 英國
  • 日本
  • 金磚四國
    • 中國
    • 巴西
    • 俄羅斯
    • 印度

第7章 專家的採訪

第8章 總論

  • 全球胃癌治療約市場現狀
  • 市場佔有率結構的今後變化
  • 主要企業
  • 各國市場佔有率結構的今後變化
  • 總論:未來展望
目錄
Product Code: PHA0125

Title:
GASTRIC CANCER DRUGS - R&D, TRENDS AND MARKET FORECASTS 2016-2026
Evaluation of Therapeutic Segments, Including Monoclonal Antibodies, Chemotherapy and Angiogenesis Inhibitors; Prediction of Leading National Markets (US, Japan, EU5 and BRIC); Investigation of Leading Products, Including Herceptin, Cyramza, Xeloda, Taxotere and Abraxane; and Assessment of R&D, Including Roche's Perjeta, the Checkpoint Inhibitor Immunotherapies Keytruda and Opdivo.

Gastric Cancer Therapies - What R&D Progress and Future Revenues Are Possible?

Are you interested in the gastric cancer drug market's future? If so, you find that sales forecasting from 2016 in our new report. See there what is possible for those products and companies. You also explore trends, results and R&D, discovering opportunities and prospects.

Visiongain's study gives revenue predictions to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and revenues those anticancer drugs for the human digestive tract can achieve.

Please read on now to explore the stomach cancer drugs industry and see what future revenue its fast expanding market could generate.

Original analysis to benefit your research, plans, decisions and proposals

The future holds great potential for pharmaceutical companies treating gastric cancer. New products enter that market and novel drug candidates reach late-stage clinical testing. Discover, from 2016, revenues and other progress that are possible.

Besides revenue forecasting to 2026, our new work shows you recent results, sales growth rates and market shares. In particular, there, you assess research and development. And our 146 page report gives you 71 tables, 38 charts and a research interview.

Our new study's purpose is to help your research, analyses and decisions on gastric cancer therapies, benefiting your authority and reputation for commercial insight. That way you can stay ahead in knowledge to help you stand out and succeed.

The following sections show how our new investigation benefits your work.

Forecasts covering the overall world market and segments for treating gastric cancer

Discover in our new analysis revenue predictions to 2026 for gastric cancer submarkets at world level, as well as a prediction for overall world sales. See what is possible for these four segments:

  • Monoclonal antibodies (mAbs)
  • Angiogenesis inhibitors
  • Chemotherapy
  • Pipeline candidates and other agents.

Where lie the best sales potentials? With our survey you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors' actions and outlooks. Discover, from 2016, what is possible for that market's progress and success.

With a rising incidence of gastric cancer, the demand for better and more-widely available treatments will benefit that industry and market. Explore prospects for patients, healthcare providers and pharma companies.

Our new investigation also shows you revenue predications by product, examining how those agents can succeed.

Forecasts for leading drugs - what sales are possible?

How will individual gastric cancer medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of these seven products:

  • Herceptin (trastuzumab) - Roche
  • Cyramza (ramucirumab) - Eli Lilly
  • Taxotere (docetaxel) - Sanofi
  • Xeloda (capecitabine) - Roche
  • Abraxane (paclitaxel protein-bound particle) - Celgene/Taiho Pharmaceutical/Otsuka Pharmaceutical
  • TS-1/S-1 - Taiho Pharmaceutical/Otsuka Pharmaceutical
  • Apatinib (YN968D1) - Jiangsu Hengrui Medicine/LSK BioPartners/Bukwang Pharmaceutical Co.

In our study you see how high revenues can go, including those for targeted therapies, finding products and years with highest predicted sales. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.

Discover what the future holds for treating gastric cancer. Our work also shows you geographical sales predictions.

National markets - what outlooks for those anticancer drug revenues?

Advances in the biopharma industry expand the range and use of medicines to treat gastric cancer in developed and developing countries. Our work shows you individual revenue forecasts to 2026 for 11 leading national markets:

  • The United States
  • Japan
  • Germany, the United Kingdom, France, Italy and Spain (EU5 countries)
  • Brazil, Russia, India and China (BRIC group).

With our study you assess regions with highest revenues and potential sales growth. Explore outlooks for treating gastric cancers, including discussions of patients' and healthcare providers' needs.

You also examine developments leading to novel and improved gastric cancer drugs.

R&D for those anticancer medicines - trends, innovations and progress

In our study you investigate research and development on gastric cancer. You examine advances in that oncology, assessing clinical trials and seeing what they show.

Our survey discusses 13 medicines in development for gastric cancer, including these agents:

  • Perjeta (pertuzumab) - Roche
  • Opdivo (nivolumab/ONO-4538) - Roche
  • Keytruda (pembrolizumab/MK3475) - Merck/MSD
  • TAS-118 - Taiho Pharmaceutical/Otsuka Pharmaceutical
  • TAS-102 - Taiho Pharmaceutical/Otsuka Pharmaceutical
  • NeuVax (nelipepimut-S) - Galena Biopharma/Dr. Reddy's Laboratories
  • Ipatasertib (GDC-0068/RG7440) - Genentech/Roche/Array Biopharma
  • Durvalumab (MEDI4736) - AstraZeneca/MedImmune
  • Avelumab (MSB0010718C) - Merck KGaA/Pfizer
  • Claudiximab (IMAB362) - Ganymed Pharmaceutical
  • Napabucasin (BBI608) - Boston Biomedical
  • AZD4547 - AstraZeneca
  • Dovitinib (TKI258) - Novartis.

Our work shows you what is possible. R&D gains momentum from rising disease prevalence and other forces making treatments for that cancer more widely used and in greater demand.

There explore therapeutic and commercial prospects for treating advanced gastric cancer and gastro oesophageal junction (GOJ) cancer, including adenocarcinoma, and related disease. See, from 2016, what is possible.

Events and changes affecting pharmaceutical companies treating gastric cancer

Our study explains forces shaping the industry and market, letting you explore what is happening from 2016:

  • Extension of drugs' use - gaining approval for a wider indication range, including use of predictive biomarkers
  • Existing products and their futures - leading pharma companies' strategies
  • Competition to gain drug approvals, especially from the FDA and EMA, including medicines with new targets
  • Progress in clinical trials - finding the most promising medicines, including drugs with better targeting of tumours and cancerous cells
  • Patent challenges - protecting intellectual property in a competitive market - the rise of generics and biosimilars
  • Combination therapies and other developments for biological drugs
  • Cost challenges - pricing and reimbursement, including proving value and clinical superiority.

You also gain analysis of strengths, weaknesses, opportunities and threats, assessing what drives and restrains that rising anticancer drugs segment.

Our work shows you what is possible for leading pharma companies and other specialists in biological drugs for treating gastric cancer.

Overall 2020 market value - what revenues are possible?Our work predicts that overall sales of those drugs will reach $3bn in 2020. That market will achieve fast revenue expansion from 2016 to 2026, multiplying in size. With our analysis you discover how high sales can go, seeing what is possible for those pharma companies.

In particular you examine leading players in that drug development, production and marketing, including Roche, Sanofi, Eli Lilly, Pfizer and Novartis. See what their futures hold.

7 ways Gastric Cancer Drugs - R&D, Trends and Market Forecasts 2016-2026 helps you

Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge to benefit your plans, decisions and proposals:

  • Revenues for gastric cancer drugs to 2026 - assess that overall world market's potential, seeing scope for investments, production and marketing
  • Submarket revenues to 2026 covering 4 segments - explore treatment categories, seeing their sales outlooks from 2016
  • Leading products' sales to 2026 - discover predicted revenues of 7 top drugs, assessing how well those medicines can compete and succeed
  • National market predictions to 2026 for 11 countries in the Americas, Europe and Asia - explore the best regions for demand, sales and growth
  • Research and development - see progress, trends and prospects in R&D on gastric cancer, finding technological, clinical and commercial possibilities
  • Companies, news and opinion - examine participants in that rising market, gaining insight to help you stay ahead and benefit your authority
  • Analysis of what stimulates and restrains that market - assess that industry's challenges and strengths, helping you compete and gain advantages.

That study, by our in-house analysts in the UK, gives knowledge to benefit your research and decisions. It shows data you find nowhere else. Gain information leading companies depend on.

Predictions for treating gastric cancer - gain data to help you stay ahead

With our independent study you explore products, companies, progress and possibilities. Discover the best opportunities and assess commercial potentials.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort. Also discover how you could benefit your plans, decisions, presentations, proposals and influence.

Our new investigation shows you data, trends, opportunities and forecasts for that expanding anticancer drugs market. Avoid missing out. Instead please get our report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Gastric Cancer Therapeutics: Market Overview
  • 1.2. Global Gastric Cancer Therapeutics Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Main Questions Answered by This Analytical Study
  • 1.6. Who is This Report For?
  • 1.7. Methods of Research and Analysis
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Gastric Cancer Treatment

  • 2.1. Stomach Cancer: An Overview
  • 2.2. Treatments for Stomach Cancer
  • 2.3. Defining the Gastric Cancer Therapies Market

3. Leading Stomach Cancer Drugs

  • 3.1. Herceptin (trastuzumab) - Roche: The First Targeted Drug Approved as a Gastric Cancer Treatment
    • 3.1.1. Herceptin: Treatment of HER2+ Cancer
    • 3.1.2. Herceptin: Method of Administration and Side Effects
    • 3.1.3. ToGA: Pivotal Herceptin Study Led to Approvals
    • 3.1.4. ToGA Trial Results
      • 3.1.4.1. Further Possibilities from the ToGA Results
    • 3.1.5. Herceptin Revenue Forecast 2015-2026: Losing Battle with Biosimilar Trastuzumab
  • 3.2. Cyramza (ramucirumab) - Eli Lilly
    • 3.2.1. REGARD and RAINBOW: Pivotal Cyramza Clinical Trials
    • 3.2.2. Cyramza: VEGF Targeting for the Inhibition of Angiogenesis
    • 3.2.3. Cyramza's Development: Potential as a Combination Treatment
    • 3.2.4. Cyramza Revenue Forecast 2015-2026
  • 3.3. Taxotere (docetaxel) - Sanofi
    • 3.3.1. Taxotere Revenue Forecast 2015-2026
  • 3.4. Xeloda (capecitabine) - Roche
    • 3.4.1. Xeloda Revenue Forecast 2015-2026
  • 3.5. Abraxane (paclitaxel protein-bound particles) - Celgene/ Taiho Pharmaceutical/Otsuka Pharmaceutical
    • 3.5.1. Abraxane Revenue Forecast 2015-2026
  • 3.6. TS-1 (S-1/Teysuno) - Taiho Pharmaceutical/Otsuka Pharmaceutical
    • 3.6.1. TS-1 Revenue Forecast 2015-2026
  • 3.7. Apatinib (YN968D1) - Jiangsu Hengrui Medicine/LSK BioPartners/Bukwang Pharmaceutical Company
  • 3.7.1. Apatinib Revenue Forecast 2015-2026

4. The Gastric Cancer Treatment R&D Pipeline Analysis 2016-2026

  • 4.1. The Importance of R&D in the Gastric Cancer Treatment Industry
  • 4.2. Perjeta (pertuzumab) - Roche - A Novel HER2 Targeting Mechanism
  • 4.3. Opdivo (nivolumab/ONO-4538) - Bristol-Myers Squibb
  • 4.4. Keytruda (pembrolizumab/MK3475) - Merck/MSD
  • 4.5. TAS-118 - Taiho Pharmaceutical/Otsuka Pharmaceuticals
  • 4.6. TAS-102 - Taiho Pharmaceutical/Otsuka Pharmaceuticals/Servier
  • 4.7. NeuVax (nelipepimut-S) - Galena Biopharma/Dr. Reddy's Laboratories
  • 4.8. Ipatasertib (GDC-0068/RG7440) - Genentech/Roche/Array BioPharma
  • 4.9. Durvalumab (MEDI4736) - AstraZeneca/MedImmune
  • 4.10. Avelumab- (MSB0010718C) - Merck KGaA/Pfizer
  • 4.11. Claudiximab (IMAB362) - Ganymed Pharmaceutical
  • 4.12. Napabucasin (BBI608) - Boston Biomedical
  • 4.13. AZD4547 - AstraZeneca
  • 4.14. Dovitinib (TKI258) - Novartis
  • 4.15. The Future of the Gastric Cancer Treatment Landscape: Other Compounds of Future Interest

5. Global Gastric Cancer World Market 2015 to 2026: Forecasts and SWOT Analysis

  • 5.1. The Global Gastric Cancer Treatment Market Forecast 2015-2026
  • 5.2. World Revenue Forecasts 2015-2026: Changing Market Shares for the Gastric Cancer Treatment Market
  • 5.3. Chemotherapy Segment Forecast, 2015-2026
  • 5.4. Monoclonal Antibodies Segment Forecast, 2015-2026
  • 5.5. Angiogenesis Inhibitors Segment Forecast, 2015-2026
  • 5.6. Drivers and Restraints of the Gastric Cancer Treatment Market 2015 to 2026
    • 5.6.1. Factors Driving Growth in the Gastric Cancer Treatment Market 2015 to 2026
      • 5.6.1.1. A Rise in the At-Risk Population Will Drive Growth
      • 5.6.1.2. Premium-Pricing of Drugs Will Generate Revenue
      • 5.6.1.3. There is High Unmet Need for Novel Treatments to Improve Poor Prognosis
      • 5.6.1.4. Biomarker Development is Critical to Improving Diagnosis and Prognosis of Gastric Cancer
      • 5.6.1.5. Combination Therapies: Lowering Associated Toxicities and Improving the Safety Profile for Treatments
    • 5.6.2. Factors Restraining the Gastric Cancer Treatment Market 2015 to 2026
      • 5.6.2.1. Loss of Patent Protection Will Open the Market to Generic and Biosimilar Erosion
      • 5.6.2.2. Affordability of Treatment Will Restrain Market Growth Because of Healthcare Budgets
      • 5.6.2.3. Patients are Developing Resistance to Treatment
  • 5.7. SWOT Analysis of the Gastric Cancer Treatment Market 2015 to 2026

6. Leading National Markets for the Gastric Cancer Treatment Market 2015-2026

  • 6.1. Regional Breakdown of the World Gastric Cancer Treatment Market
  • 6.2. World Gastric Cancer Treatment Market: Regional Forecasts 2015-2026
    • 6.2.1. How Will Regional Market Shares Change to 2026?
  • 6.3. The US Gastric Cancer Treatment Market 2015 to 2026
  • 6.4. The EU5 Gastric Cancer Treatment Market 2015 to 2026
    • 6.4.1. The Gastric Cancer Treatment Market in Germany to 2026
    • 6.4.2. The Gastric Cancer Treatment Market in Italy to 2026
    • 6.4.3. The Gastric Cancer Treatment Market in Spain to 2026
    • 6.4.4. The Gastric Cancer Treatment Market in France to 2026
    • 6.4.5. The Gastric Cancer Treatment Market in UK to 2026
  • 6.5. The Japanese Gastric Cancer Treatment Market 2015-2026
  • 6.6. The Gastric Cancer Treatment Market in the Emerging Market: BRIC Market Forecast 2015-2026
    • 6.6.1. The Gastric Cancer Treatment Market in China to 2026
    • 6.6.2. The Gastric Cancer Treatment Market in Brazil to 2026
    • 6.6.3. The Gastric Cancer Treatment Market in Russia to 2026
    • 6.6.4. The Gastric Cancer Treatment Market in India to 2026

7. Research Interview

  • 7.1. Interview with Dr Jun Cai, MD, PhD, Senior Research Fellow, Cardiff China Research Collaborative, Cardiff University, Cardiff, Wales, UK
    • 7.1.1. Biomarkers: An Opportunity in Gastric Cancer Treatment
    • 7.1.2. Challenges in Developing Gastric Cancer Treatments
    • 7.1.3. The Benefits of Using Biomarkers
    • 7.1.4. Targeted Treatment: VEGF Inhibitors

8. Conclusions

  • 8.1. The World Gastric Cancer Treatment Market in 2015
  • 8.2. Market Share Distribution Will Differ Over the Forecast Period
  • 8.3. Leading Gastric Cancer Treatment Drug Companies
  • 8.4. National Market Segments: Changes in Market Share Over the Forecast Period
  • 8.5. Concluding Remarks: The Future of the Gastric Cancer Treatment Market

List of Tables

  • Table 3.1: FDA Approved Indications of Herceptin
  • Table 3.2: Selected Approval Dates for Herceptin for Gastric Cancer Treatment by Region
  • Table 3.3: Herceptin Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 3.4: Herceptin Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 3.5: FDA Approvals for Cyramza
  • Table 3.6: Selected Approvals for Cyramza for Gastric Cancer Treatment by Region
  • Table 3.7: Selected Cyramza Phase 1 and 2 Clinical Trials, 2016
  • Table 3.8: Cyramza Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 3.9: Cyramza Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 3.10: Taxotere Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 3.11: Taxotere Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 3.12: Xeloda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 3.13: Xeloda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 3.14: Abraxane Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 3.15: Abraxane Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 3.16: TS-1 Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 3.17: TS-1 Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 3.18: Selected Clinical Trials for Apatinib, 2016
  • Table 3.19: Apatinib Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 3.20: Apatinib Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 4.1: Selected Gastric Cancer Pipeline Developments, 2016
  • Table 4.2: HER2 Structure
  • Table 4.3: S-1 Structure, 2016
  • Table 4.4: Other Compounds of Interest for Gastric Cancer Treatment, 2016
  • Table 5.1: Global Gastric Cancer Treatment Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.2: Global Gastric Cancer Treatment Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.3: Top Three Gastric Cancer Treatment Drugs by Revenue ($bn), 2015
  • Table 5.4: Global Market for Gastric Cancer Drug Treatments: Revenues ($bn) and Market Shares (%) by Class, 2015
  • Table 5.5: Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2015-2020
  • Table 5.6: Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2021-2026
  • Table 5.7: Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Changing Market Shares (%), 2015-2026
  • Table 5.8: Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.9: Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.10: Monoclonal Antibodies Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.11: Monoclonal Antibodies Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.12: Angiogenesis Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 5.13: Angiogenesis Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 5.14: SWOT: Strengths, Weaknesses, Opportunities and Threats in the Gastric Cancer Treatment Market, 2016-2026
  • Table 6.1: Gastric Cancer Treatment Market: Revenues ($bn) and Market Shares (%) by Region, 2015
  • Table 6.2: Gastric Cancer Treatment Market: Regional Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.3: Gastric Cancer Treatment Market: Regional Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.4: US Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.5: US Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.6: EU5 Gastric Cancer Treatment Market: Revenue ($bn) and Market Share (%) by Leading Country, 2015
  • Table 6.7: EU5 Gastric Cancer Treatment National Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.8: EU5 Gastric Cancer Treatment National Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.9: German Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.10: German Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.11: Italian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.12: Italian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.13: Spanish Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.14: Spanish Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.15: French Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.16: French Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.17: UK Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.18: UK Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.19: Japanese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.20: Japanese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.21: Pharma Contract Manufacturing Market: Emerging Market Revenue ($bn) and Market Share (%) by Top Country, 2015
  • Table 6.22: Gastric Cancer Treatment Market: Leading Emerging Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.23: Gastric Cancer Treatment Market: Leading Emerging Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.24: Chinese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.25: Chinese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.26: Brazilian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.27: Brazilian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.28: Russian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.29: Russian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 6.30: Indian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
  • Table 6.31: Indian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
  • Table 8.1: Gastric Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2015, 2020, and 2026
  • Table 8.2: Gastric Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2015, 2020, and 2026

List of Figures

  • Figure 1.1: Global Gastric Cancer Therapeutics Market Segmentation Overview, 2016
  • Figure 3.1: Herceptin Forecast: Revenue ($bn), 2015-2026
  • Figure 3.2: Cyramza Forecast: Revenue ($bn), 2015-2026
  • Figure 3.3: Taxotere Forecast: Revenue ($bn), 2015-2026
  • Figure 3.4: Xeloda Forecast: Revenue ($bn), 2015 -2026
  • Figure 3.5: Abraxane Forecast: Revenue ($bn), 2015-2026
  • Figure 3.6: TS-1 Forecast: Revenue ($bn), 2015-2026
  • Figure 3.7: Apatinib Forecast: Revenue ($bn), 2015-2026
  • Figure 5.1: Global Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 5.2: Global Market for Gastric Cancer Treatments: Market Shares by Class (%), 2015
  • Figure 5.3: Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Market Sizes ($bn), 2015 to 2026
  • Figure 5.4: Global Market for Gastric Cancer Treatment Drugs by Class: Market Shares (%), 2020
  • Figure 5.5: Global Market for Gastric Cancer Treatment Drugs by Class: Market Shares (%), 2026
  • Figure 5.6: Chemotherapy Segment: Revenues ($bn), 2015-2026
  • Figure 5.7: Monoclonal Antibodies Segment: Revenues ($bn), 2015-2026
  • Figure 5.8: Angiogenesis Inhibitors Segment: Revenues ($bn), 2015-2026
  • Figure 5.9: Gastric Cancer Treatment Market: Main Drivers and Restraints, 2016-2026
  • Figure 6.1: Gastric Cancer Treatment Market: Share (%) by Region, 2015
  • Figure 6.2: Forecast of Regional and National Gastric Cancer Treatment Market, Revenue ($bn), 2015-2026
  • Figure 6.3: Gastric Cancer Treatment Market: Share (%) by Region, 2020
  • Figure 6.4: Gastric Cancer Treatment Market: Share (%) by Region, 2026
  • Figure 6.5: US Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 6.6: EU5 Gastric Cancer Treatment Market: Share (%) by Country, 2015
  • Figure 6.7: EU5 Gastric Cancer Treatment National Market Forecasts: Revenue ($bn), 2015-2026
  • Figure 6.8: German Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 6.9: Italian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 6.10: Spanish Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 6.11: French Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 6.12: UK Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 6.13: Japanese Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 6.14: Gastric Cancer Treatment Market: Emerging Market Share (%) by Top Country, 2015
  • Figure 6.15: Forecast of the Emerging Gastric Cancer Treatment Market, Revenue ($bn), 2015-2026
  • Figure 6.16: Chinese Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 6.17: Brazilian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 6.18: Russian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 6.19: Indian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
  • Figure 8.1: The Gastric Treatment Market Forecast by Class: Market Sizes ($bn), 2015, 2020, and 2026
  • Figure 8.2: Gastric Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2015, 2020, and 2026

Companies Listed

  • Abraxis Bioscience
  • Agilent Technologies
  • American Association for Cancer Research
  • Amgen
  • AMNOG (Act of the Reform of the Market for Medicinal Products)
  • Apotex
  • Array BioPharma
  • ASCO (American Society of Clinical Oncology)
  • AstraZeneca
  • Biocad
  • Biocon
  • Boston Biomedical (subsidiary of Sumitomo Dainippon Pharma)
  • British Association for Cancer Research
  • Bukwang Pharmaceutical Company
  • Cancer Foundation
  • Cardiff China Research Collaborative
  • Cardiff University
  • Celgene
  • Celltrion
  • CFDA (China Food and Drug Administration)
  • CHMP (Committee for Medicinal Products for Human Use)
  • Chugai Pharmaceutical
  • Chugai Pharmaceuticals
  • CP Guojian Pharmaceutical
  • Dako (subsidiary of Agilent Technologies)
  • Dr. Reddy's Laboratories
  • EC (European Commission)
  • EFPIA (European Federation of Pharmaceutical Industries and Associations)
  • Eli Lilly
  • Emcure Pharmaceuticals
  • EU (European Union)
  • European Association for Cancer Research
  • European Organisation for Research and Treatment and Cancer (EORTC)
  • FDA (US Food and Drug Administration)
  • Galena Biopharma
  • Ganymed Pharmaceutical
  • Genentech (subsidiary of Roche)
  • Halozyme Therapeutics
  • Hospira
  • Japanese Society of Pathology
  • Jiangsu Hengrui Medicine
  • KFDA (Korea Food and Drug Administration)
  • LSK BioPartners
  • Medarex
  • MedImmune (subsidiary of AstraZeneca)
  • Merck & Co
  • Merck (MSD)
  • Merck KGaA
  • Merck Serono (subsidiary of Merck KGaA)
  • MFDS (Korean Ministry of Food and Drug Safety)
  • MHLW (Ministry of Health, Labour, and Welfare)
  • Ministry of Health
  • Mylan
  • NanoString Technologies
  • NHS (National Health Service)
  • NICE (the National Institute for Health and Care Excellence)
  • Novartis
  • ONO Pharmaceutical
  • Otsuka Pharmaceutical
  • Otsuka Pharmaceutical/Otsuka Group
  • Pfizer
  • PMDA (Pharmaceuticals and Medical Devices Agency)
  • Puma Biotechnology
  • Roche
  • Sanofi
  • Servier
  • Sumitomo Dainippon Pharma
  • Taiho Pharmaceutical
  • UCLA (University of California, Los Angeles)
  • Unified Health System (SUS, Sistema Único de Saúde)
  • United Nations
  • US Court of Appeals
  • WHO (World Health Organization)
  • World Cancer Research Fund International
Back to Top